

## SPECIALTY QUANTITY LIMIT PROGRAM

### THALOMID (thalidomide)

#### I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If the member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization. The recommended dosing parameters for treatment or prevention of multiple myeloma or erythema nodosum leprosum (ENL) fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

#### II. COVERED QUANTITIES

| Medication                            | FDA-recommended dosing  | Standard Limit | Exception Limit  |
|---------------------------------------|---|----------------|------------------|
| Thalomid (thalidomide) capsules 50mg  | Multiple myeloma: 200 mg orally once daily  | 28 per 28 days | Not applicable   |
| Thalomid (thalidomide) capsules 100mg | Erythema nodosum leprosum (ENL): 100 to 300 mg/day for an episode of cutaneous ENL. Up to 400 mg/day for severe cutaneous ENL | 28 per 28 days | Not applicable   |
| Thalomid (thalidomide) capsules 150mg |   | 56 per 28 days | Not applicable   |
| Thalomid (thalidomide) capsules 200mg |   | 56 per 28 days | 244 per 28 days* |

\* Exception limit to address chronic graft-versus-host disease (GVHD).

#### III. REFERENCES

1. Thalomid [package insert]. Summit, NJ: Celgene Corporation; August 2015.